The target audience for Larimar Therapeutics are patients with rare diseases, specifically Friedreich's ataxia. This is evident from their focus on developing treatments for this disease and their partnerships with organizations dedicated to supporting FA research and patients. Investors and medical professionals interested in rare diseases and gene therapy may also be considered part of their target audience.